🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

RecruitingPhase 4Ages 18 Years - anyAllThomas Benfield
NCT04875819 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

MENPI is an investigator-initiated single-centre randomized controlled trial which aims to assess the efficacy and safety of meningococcal and pneumococcal vaccination in adults living with HIV receiving antiretroviral treatment. Participants are randomized 1:1 to either a two-dose Menveo® and Bexsero® regimen or a Prevenar13®/Pneumovax23® prime-boost regimen at day 0 and day 60 and cross over on day 90. All participants will follow an identical follow up program including plasma collection, pharyngeal swab, and adverse event registration. Immunogenicity will be determined on venous blood sampled at 30 days post-vaccination and yearly for five years.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Seropositive for HIV-1 * Recipient of ART * Plasma HIV-RNA \< 500 copies/ml * Patients written consent obtained Exclusion Criteria: * Pregnancy or breastfeeding * History of meningococcal or pneumococcal vaccination * Allergies towards any of the vaccine components * Temperature \> 38 ᵒC * Sign of bacterial infection * Previous known or suspected disease caused by N. meningitidis * Active AIDS associated illness * Active malignancy * End-stage renal or liver disease * Bleeding disorder * Recipient of any blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within the last month * Use of immunosuppressive agents (corticosteroids, cancer chemotherapeutic agents etc.)
💊

What it tests

  • Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine
  • 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
📍

Where

1 site
Hvidovre Hospital
Hvidovre, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy